Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Australian researchers have begun injecting insulin-producing cells taken from healthy pigs into people with type 1 diabetes in an attempt to cure their condition.

Crucially, the scientists claim to have all but eliminated the risk of infection from the animal transplants. Transplanted cells are encased in a porous gel that protects them from attack by the host immune system, doing away with the need for harmful immuno-supressive medication.

The trials follow preliminary tests in which two volunteers with type 1 diabetes, an autoimmune disease that results in the destruction of the insulin-producing islet cells in the pancreas. Insulin is vital for controlling blood-sugar levels, and patients with the disease currently face life-long insulin injections to prevent life-threatening surges in blood-glucose levels. The volunteers demonstrated independence from insulin shots for several months when treated by the technique, according to project leader Robert Elliott, cofounder and medical director of Living Cell Technologies. Preliminary tests were also done on primates, who suffered no side effects from the treatment.

“In the preliminary tests we showed that there is a clear benefit and a vanishingly small risk,” Elliot says. “So we have demonstrated what we need to go ahead with this large clinical trial.” The preliminary results were reported at the annual meeting of the International Society for Cell Therapy in May this year.

The radical technique will now be tested on 18 volunteers in a larger clinical study that will take place in Russia and New Zealand, because a moratorium on xenotransplantation exists in Australia–although that is up for review later this year.

Volunteers in New Zealand began receiving the encapsulated porcine cells in their abdomens this week in a “simple procedure” done under local anesthetic, Elliot says. All the volunteers have type 1 diabetes.

The Australian researchers are deliberately including in the trial some patients with unstable diabetes, whose condition is poorly controlled by insulin treatment. After an initial two-month evaluation period, the volunteers will continue to be monitored for months or years. If the transplants are successful, the researchers hope to be able to wean the subjects off insulin injections.

3 comments. Share your thoughts »

Credit: Living Cell Techologies

Tagged: Biomedicine, Diabetes, insulin, insulin-producing cells

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me